Atlanthene Pharma Co.
Latest round
- Series A
Last raised
- May 2025
Total raised
- Undisclosed
Investors
- 2
About Atlanthene Pharma Co.
Founded in 2022 and headquartered in Osaka-shi, Japan, Atransen Pharma Ltd. focuses on the research and development of cancer therapies, particularly targeting LAT1 inhibitors. The company has completed one deal as of May 30, 2025. Details regarding the founder's history or previous ventures are not provided. Atransen Pharma Ltd. specializes in developing innovative cancer therapies, focusing on treatments that target amino acid transporters and particularly LAT1 inhibitors. These inhibitors are designed to inhibit the uptake of essential amino acids critical for tumor growth, thus suppressing cancer cell proliferation. The company aims to provide treatment options with fewer side effects than traditional therapies, catering to healthcare providers, hospitals, and oncology clinics across Japan, the United States, and Europe. Atransen Pharma Ltd. generates revenue primarily through partnerships and collaborations with healthcare institutions and pharmaceutical companies. Their business model involves B2B transactions, where LAT1 inhibitor products are supplied to hospitals and clinics for cancer treatment. Revenue is structured around contractual agreements, which may include licensing fees, milestone payments, and royalties based on product sales. These strategic partnerships are integral to the company's financial growth as it continues to advance its clinical pipeline. In May 2025, Atransen Pharma Ltd. The company aims to introduce new products into the market and expand its footprint into additional regions, including North America and Europe, by targeting these markets for its innovative cancer therapies.
Who invested in Atlanthene Pharma Co.
2 investors across 1 round
See all investors in Atlanthene Pharma Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
May 30, 2025
Amount
Undisclosed
Investors
Questions about Atlanthene Pharma Co.
Who invested in Atlanthene Pharma Co.?
Atlanthene Pharma Co. has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Atlanthene Pharma Co. raised?
Atlanthene Pharma Co. has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Atlanthene Pharma Co. last raise money?
Atlanthene Pharma Co.'s most recent round on record is a Series A, in May 2025.
What does Atlanthene Pharma Co. do?
Founded in 2022 and headquartered in Osaka-shi, Japan, Atransen Pharma Ltd.
Where is Atlanthene Pharma Co. headquartered?
Atlanthene Pharma Co. is headquartered in Osaka-shi, Japan.
Which VCs invest in companies like Atlanthene Pharma Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Atlanthene Pharma Co.'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Atlanthene Pharma Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.